FDA Public Meeting On Drug Safety Communication Set For Dec. 7-8
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency seeks public input on effectiveness of currently used risk communication tools; meeting is part of ongoing drug safety initiative.
You may also be interested in...
FDA Drug Safety Board To Meet Every Six Weeks
The board discussed FDA's recent action on fentanyl transdermal patches (J&J's Duragesic and generics) and Purdue's Palladone (hydromorphone extended-release) during a July 27 meeting, FDA's meeting summary says.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.